Ensysce Biosciences has launched its groundbreaking product, PF614-MPAR, as the inaugural opioid of its kind designed to offer oral overdose protection across all drug classes.
PF614-MPAR is designed to deliver precise pain relief within prescribed thresholds while effectively kerbing the risk of accidental or intentional overdose. By implementing a mechanism that halts opioid release upon exceeding safe consumption levels, PF614-MPAR signifies a potential breakthrough in pain management.
The introduction of PF614-MPAR has the potential to mark a significant advancement in the treatment landscape for severe pain conditions, potentially paving the way for a new therapeutic category. This innovative approach not only promises enhanced safety but also holds the prospect of mitigating the opioid crisis by reducing the risk associated with traditional opioids.
Prescription overdose deaths in the United States have reached alarming levels, with nearly two deaths per hour, according to the latest data from the Centres for Disease Control.
This crisis underscores the urgent need for safer opioids that effectively manage severe pain while mitigating the risks of abuse and oral overdose. Safer alternatives for managing severe pain while reducing the risk of abuse and overdose are crucial to address this issue.
In the Phase 1 study, PF614-MPAR-101 has showcased a distinct capability to offer protection against excessive oral opioid consumption, marking a unique advancement within the opioid class.
The U.S Food and Drug Administration (FDA) that it has granted breakthrough therapy designation (BTD) for PF614-MPAR, a groundbreaking next-generation opioid.
